What is HC Wainwright’s Estimate for Genmab A/S Q1 Earnings?

Genmab A/S (NASDAQ:GMAB) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Genmab A/S in a research note issued on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju expects that the company will earn $0.18 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q2 2025 earnings at $0.39 EPS, Q3 2025 earnings at $0.43 EPS, Q4 2025 earnings at $0.49 EPS and FY2025 earnings at $1.50 EPS.

Several other equities analysts have also commented on GMAB. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Redburn Atlantic initiated coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating for the company. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $21.13 on Friday. Genmab A/S has a one year low of $19.85 and a one year high of $31.88. The company has a 50 day moving average price of $21.08 and a 200 day moving average price of $23.93. The firm has a market capitalization of $13.98 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the previous year, the company posted $0.47 EPS.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its holdings in Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after purchasing an additional 827 shares in the last quarter. R Squared Ltd acquired a new stake in Genmab A/S during the 4th quarter valued at $93,000. Blue Trust Inc. grew its holdings in Genmab A/S by 33.4% during the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after purchasing an additional 1,442 shares in the last quarter. SG Americas Securities LLC grew its holdings in Genmab A/S by 82.7% during the 4th quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock valued at $551,000 after purchasing an additional 11,949 shares in the last quarter. Finally, Crossmark Global Holdings Inc. grew its holdings in Genmab A/S by 8.8% during the 4th quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company’s stock valued at $868,000 after purchasing an additional 3,377 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.